[{"nct_id": "NCT00441025", "brief_title": "The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL", "brief_summary": "\n      The purpose of this study is to determine whether the treatment of Alemtuzumab in\n      combination with CHOP(cyclophosphamide,doxorubicin,vincristine and prednisolone) are\n      effective as first line treatment in patients with peripheral T-cell lymphoma.\n    ", "detailed_description": "\n      Peripheral T-cell lymphomas (PTCL) are more common in Asia than in Europe and United States\n      (17-40% vs. 5-10%). Most studies reported a poorer prognosis for PTCL compared to B-cell\n      non-Hodgkin's lymphomas (NHL).\n\n      CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) is currently regarded as\n      a standard chemotherapy regimen for patients with newly diagnosed NHL.\n\n      Alemtuzumab (Campath-1H) is a humanized monoclonal antibody that targets CD52, a cell\n      surface protein present at high density on most normal and malignant B and T\n      lymphocytes.Malignant T cells express particularly high numbers of CD52 cell surface markers\n      (approximately 500,000 molecules/lymphocytes),T-cell malignancies may thus be particularly\n      responsive to alemtuzumab.\n\n      As the response rate tend to be higher in patients newly diagnosed with PTCL, this study\n      evaluates the efficacy of alemtuzumab in combination with CHOP administered as up-front\n      therapy in patients newly diagnosed with PTCL in terms of response rate and overall\n      survival.\n    ", "overall_status": "Terminated", "condition": "Peripheral T-Cell Lymphoma", "eligibility": "\n        Inclusion Criteria:\n\n          -  Patients must have a diagnosis of one of the following histologic types according to\n             the WHO classification:\n\n               -  Angioimmunoblastic T-cell lymphoma\n\n               -  Extranodal NK/T-cell lymphoma,nasal type\n\n               -  Enteropathy-type T-cell lymphoma\n\n               -  Hepatosplenic gamma-delta T-cell lymphoma\n\n               -  Subcutaneous panniculitis-like T-cell lymphoma\n\n               -  Anaplastic large-cell lymphoma,T/null cell,primary systemic type\n\n               -  Peripheral T-cell lymphoma,not otherwise characterized\n\n          -  Newly diagnosed,age 15-65 years.\n\n          -  Complete work up for baseline evaluation and measurement (Appendix B)\n\n          -  Patient's free written inform consent.\n\n        Exclusion Criteria:\n\n          -  Patients with a known hypersensitivity to murine proteins or to any component of\n             alemtuzumab.\n\n          -  Patients who have received prior antilymphoma treatment with chemotherapy or\n             radiotherapy\n\n          -  Patients with poor performance status (PS;ECOG criteria of 3-4)(Appendix C).\n\n          -  Serologic evidence of HCV and HCV RNA of chronic hepatitis.\n\n          -  Serologic evidence of HBV and HBV RNA of chronic hepatitis.\n\n          -  Patients with history of impaired cardiac status or myocardial infarction.\n\n          -  Patients with serum creatinine >= 1.8 mg/dl,bilirubin >= 1.5 times upper limit of\n             normal range,SGOT or SGPT >= 3 times upper limit of normal range, unless due to tumor\n             involvement.\n\n          -  Patients with active uncontrolled infection,active non-malignant gastric or duodenal\n             ulcer, uncontrolled diabetes mellitus or other severe medical conditions which would\n             preclude aggressive cytotoxic chemotherapy.\n\n          -  Active secondary malignancy.\n\n          -  Pregnant or lactating women.\n\n          -  Serious medical or psychiatric illness which prevent informed consent.\n\n          -  Patients who are likely to lost to follow up (eg, unwilling or difficult to\n             return,cannot be contacted).\n      ", "gender": "All", "gender_based": null, "minimum_age": 15, "maximum_age": 65, "keyword": ["MabCampath + CHOP in PTCL"], "mesh_term": ["Lymphoma", "Lymphoma, T-Cell", "Lymphoma, T-Cell, Peripheral"]}, {"nct_id": "NCT00930605", "brief_title": "The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)", "brief_summary": "\n      1. Primary Research Question What are the rates of complete response (CR), partial\n           response (PR), progression free survival (PFS) and overall survival (OS) in adult\n           patients newly diagnosed with Peripheral T-Cell Lymphoma (PTCL) who are treated with\n           alemtuzumab given in combination with CHOP (cyclophosphamide, doxorubicin, vincristine\n           and prednisolone) and ESHAP (etoposide, methylprednisolone, cisplatin, cytosine\n           arabinoside) administered as an up-front treatment?\n\n        2. Secondary Research Question What is the incidence of life-threatening toxicities (grade\n           3 and 4, according to WHO criteria, Appendix A) in the patients?\n    ", "detailed_description": "\n      Alemtuzumab (Campath-1H) is a humanized monoclonal antibody that targets CD52, a cell\n      surface protein present at high density on most normal and malignant B and T lymphocytes.\n\n      CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) is currently regarded as\n      a standard chemotherapy regimen for patients with newly diagnosed NHL.\n\n      ESHAP (etoposide, methylprednisolone, cisplatin, cytosine arabinoside) chemotherapy was\n      invented in 1994. The regimen was aimed to salvage NHL patients who were relapsing or\n      refractory to front-line, mostly doxorubicin-based, chemotherapy.Major toxicities were\n      myelosuppression; 30% of the patients developed febrile neutropenia and was admitted for\n      parenteral antibiotics. Treatment-related deaths, mostly from uncontrolled sepsis, occurred\n      in 4% of the patients. Because of its efficacy and tolerable toxicities, at present, ESHAP\n      is one of the salvage chemotherapy regimens most frequently administered to patients\n      especially prior to autologous stem cell transplantation.\n\n      Recently, our unit had reported the efficacy of the combination of standard CHOP\n      chemotherapy and ESHAP and high-dose therapy with autologous stem cell transplantation or\n      rituximab given as upfront therapy in patients newly diagnosed as poor prognosis aggressive\n      NHL (high- and high-intermediate risk groups according to the international index).15,16\n      According to the previous institutional experience as well as the efficacy of the\n      combination of CHOP and ESHAP in patients with high-risk aggressive lymphoma, we would like\n      therefore to determine the outcome of alemtuzumab given in combination with CHOP and ESHAP\n      in patients newly diagnosed with PTCL, the effectiveness of which has not been known.\n    ", "overall_status": "Completed", "condition": "Peripheral T-cell Lymphoma", "eligibility": "\n        Inclusion Criteria:\n\n          1. Patients must have a diagnosis of one of the following histologic types according to\n             the WHO classification:\n\n               -  Angioimmunoblastic T-cell lymphoma\n\n               -  Extranodal NK/T-cell lymphoma, nasal type\n\n               -  Enteropathy-type T-cell lymphoma\n\n               -  Hepatosplenic gamma-delta T-cell lymphoma\n\n               -  Subcutaneous panniculitis-like T-cell lymphoma\n\n               -  Anaplastic large-cell lymphoma, T/null cell, primary systemic type\n\n               -  Peripheral T-cell lymphoma, not otherwise characterized\n\n                    -  All biopsy specimens including patients whose diagnosis have been made\n                       outside King Chulalongkorn Memorial Hospital will be reviewed by an expert\n                       hematopathologist at Department of Pathology, King Chulalongkorn Memorial\n                       Hospital.\n\n          2. Newly diagnosed, age 15 - 65 years.\n\n          3. Complete work up for baseline evaluation and measurement (Appendix B).\n\n          4. Patient's free written inform consent.\n\n        Exclusion Criteria:\n\n          1. Patients with a known hypersensitivity to murine proteins or to any component of\n             alemtuzumab.\n\n          2. Patients who have received prior antilymphoma treatment with chemotherapy or\n             radiotherapy.\n\n          3. Patients with poor performance status (PS; ECOG criteria of 3-4)(Appendix C).\n\n          4. Serologic evidence of human immunodeficiency virus exposure.\n\n          5. Patients with history of impaired cardiac status or myocardial infarction.\n\n          6. Patients with serum creatinine > 1.8 mg/dl, bilirubin > 1.5 times upper limit of\n             normal range, SGOT or SGPT > 3 times upper limit of normal range, unless due to tumor\n             involvement.\n\n          7. Patients with active uncontrolled infection, active non-malignant gastric or duodenal\n             ulcer, uncontrolled diabetes mellitus or other severe medical conditions which would\n             preclude aggressive cytotoxic chemotherapy.\n\n          8. Pregnant or lactating women.\n\n          9. Serious medical or psychiatric illness which prevent informed consent.\n\n         10. Patients who are likely to lost to follow up (e.g., unwilling or difficult to return,\n             cannot be contacted).\n      ", "gender": "All", "gender_based": null, "minimum_age": 15, "maximum_age": 65, "keyword": [], "mesh_term": ["Lymphoma", "Lymphoma, T-Cell", "Lymphoma, T-Cell, Peripheral"]}, {"nct_id": "NCT00823524", "brief_title": "Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer", "brief_summary": "\n      RATIONALE: Giving an infusion of natural killer cells from a donor after a donor stem cell\n      transplant may help kill any remaining cancer cells after the transplant.\n\n      PURPOSE: This phase I/II trial is studying the side effects and best dose of donor natural\n      killer cells when given after a donor stem cell transplant in treating patients with\n      advanced cancer.\n    ", "detailed_description": "\n      OBJECTIVES:\n\n      Primary\n\n        -  To assess the safety of donor natural killer (NK) cell infusion after\n           HLA-mismatched/haploidentical allogeneic hematopoietic stem cell transplantation from a\n           familial donor in patients with advanced malignant disorders.\n\n        -  To determine the maximum number of donor NK cells that can be safely given to these\n           patients.\n\n      Secondary\n\n        -  To assess the clinical efficacy donor NK cell infusion, in terms of tumor response,\n           response duration, and survival, in patients with progressive or recurrent malignant\n           disorders.\n\n      OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.\n\n        -  Phase I: Patients receive an infusion of donor natural killer (NK) cells on days 18 and\n           21.\n\n        -  Phase II: Patients receive an infusion of donor NK cells on days 14 and 21. After\n           completion of study treatment, patients are followed periodically.\n    ", "overall_status": "Completed", "condition": "Brain and Central Nervous System Tumors", "eligibility": "\n        DISEASE CHARACTERISTICS:\n\n          -  Diagnosis of a malignant disorder (hematologic malignancies or solid tumors)\n\n               -  Advanced disease\n\n          -  Has undergone prior allogeneic hematopoietic stem cell transplantation (HSCT) from an\n             HLA-mismatched/haploidentical familial donor\n\n          -  Progressive or recurrent disease, as defined by any of the following (phase II):\n\n               -  Peripheral blood blast > 20% with bone marrow aspirate showing > 5% leukemic\n                  cells (in patients with acute leukemia)\n\n               -  Detection of metaphases in the marrow with the same clonal cytogenetic\n                  abnormalities as identified before HSCT (or by FISH markers, if appropriate) (in\n                  patients with acute leukemia or high-risk myelodysplastic syndromes [MDS])\n\n               -  Persistent cytopenia with bone marrow aspirate showing various degrees of\n                  dysplasia involving \u2265 1 cell lineage (in patients with high-risk MDS)\n\n               -  Enlargement of pre-existing measurable lesions by 20% according to RECIST\n                  criteria (in patients with solid tumors or lymphoma)\n\n               -  Appearance of new metastatic lesions, including pleural effusion or ascites,\n                  radiologically typical for metastases or confirmed as such by cytology (in\n                  patients with solid tumors or lymphoma)\n\n          -  Measurable disease (phase II)\n\n        PATIENT CHARACTERISTICS:\n\n          -  Karnofsky performance status 70-100%\n\n          -  Total bilirubin < 3.0 mg/dL\n\n          -  AST < 5 times upper limit of normal\n\n          -  Creatinine < 3 mg/dL\n\n          -  Not pregnant or nursing\n\n          -  No clinically evident cardiac or pulmonary failure\n\n        PRIOR CONCURRENT THERAPY:\n\n          -  See Disease Characteristics\n      ", "gender": "All", "gender_based": null, "minimum_age": 15, "maximum_age": 75, "keyword": ["accelerated phase chronic myelogenous leukemia", "acute undifferentiated leukemia", "adult acute myeloid leukemia with 11q23 (MLL) abnormalities", "adult acute myeloid leukemia with inv(16)(p13;q22)", "adult acute myeloid leukemia with t(15;17)(q22;q12)", "adult acute myeloid leukemia with t(16;16)(p13;q22)", "adult acute myeloid leukemia with t(8;21)(q22;q22)", "atypical chronic myeloid leukemia, BCR-ABL1 negative", "blastic phase chronic myelogenous leukemia", "chronic myelomonocytic leukemia", "chronic phase chronic myelogenous leukemia", "mast cell leukemia", "meningeal chronic myelogenous leukemia", "progressive hairy cell leukemia, initial treatment", "prolymphocytic leukemia", "recurrent adult acute lymphoblastic leukemia", "recurrent adult acute myeloid leukemia", "recurrent adult T-cell leukemia/lymphoma", "refractory chronic lymphocytic leukemia", "refractory hairy cell leukemia", "relapsing chronic myelogenous leukemia", "secondary acute myeloid leukemia", "stage III adult T-cell leukemia/lymphoma", "stage III chronic lymphocytic leukemia", "stage IV adult T-cell leukemia/lymphoma", "stage IV chronic lymphocytic leukemia", "T-cell large granular lymphocyte leukemia", "adult grade III lymphomatoid granulomatosis", "adult nasal type extranodal NK/T-cell lymphoma", "anaplastic large cell lymphoma", "angioimmunoblastic T-cell lymphoma", "splenic marginal zone lymphoma", "extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue", "nodal marginal zone B-cell lymphoma", "stage III adult Burkitt lymphoma", "stage III adult diffuse large cell lymphoma", "stage III adult diffuse mixed cell lymphoma", "stage III adult diffuse small cleaved cell lymphoma", "stage III adult Hodgkin lymphoma", "stage III adult immunoblastic large cell lymphoma", "stage III adult lymphoblastic lymphoma", "stage III cutaneous T-cell non-Hodgkin lymphoma", "stage III mycosis fungoides/Sezary syndrome", "stage III grade 1 follicular lymphoma", "stage III grade 2 follicular lymphoma", "stage III grade 3 follicular lymphoma", "stage III mantle cell lymphoma", "stage III marginal zone lymphoma", "stage III small lymphocytic lymphoma", "stage IV adult Burkitt lymphoma", "stage IV adult diffuse large cell lymphoma", "stage IV adult diffuse mixed cell lymphoma", "stage IV adult diffuse small cleaved cell lymphoma", "stage IV adult Hodgkin lymphoma", "stage IV adult immunoblastic large cell lymphoma", "stage IV adult lymphoblastic lymphoma", "stage IV cutaneous T-cell non-Hodgkin lymphoma", "stage IV mycosis fungoides/Sezary syndrome", "stage IV grade 1 follicular lymphoma", "stage IV grade 2 follicular lymphoma", "stage IV grade 3 follicular lymphoma", "stage IV mantle cell lymphoma", "stage IV marginal zone lymphoma", "stage IV small lymphocytic lymphoma", "recurrent adult Hodgkin lymphoma", "recurrent adult Burkitt lymphoma", "recurrent adult diffuse large cell lymphoma", "recurrent adult diffuse mixed cell lymphoma", "recurrent adult diffuse small cleaved cell lymphoma", "recurrent adult grade III lymphomatoid granulomatosis", "recurrent adult immunoblastic large cell lymphoma", "recurrent adult lymphoblastic lymphoma", "recurrent cutaneous T-cell non-Hodgkin lymphoma", "recurrent mycosis fungoides/Sezary syndrome", "recurrent grade 1 follicular lymphoma", "recurrent grade 2 follicular lymphoma", "recurrent grade 3 follicular lymphoma", "recurrent mantle cell lymphoma", "recurrent marginal zone lymphoma", "recurrent small lymphocytic lymphoma", "intraocular lymphoma", "primary central nervous system non-Hodgkin lymphoma", "primary central nervous system Hodgkin lymphoma", "post-transplant lymphoproliferative disorder", "chronic eosinophilic leukemia", "chronic neutrophilic leukemia", "primary myelofibrosis", "essential thrombocythemia", "polycythemia vera", "extramedullary plasmacytoma", "isolated plasmacytoma of bone", "stage II multiple myeloma", "stage III multiple myeloma", "primary systemic amyloidosis", "refractory multiple myeloma", "de novo myelodysplastic syndromes", "previously treated myelodysplastic syndromes", "secondary myelodysplastic syndromes", "myelodysplastic/myeloproliferative neoplasm, unclassifiable", "cutaneous B-cell non-Hodgkin lymphoma", "Waldenstr\u00f6m macroglobulinemia", "unspecified adult solid tumor, protocol specific"], "mesh_term": ["Lymphoma", "Disease", "Syndrome", "Leukemia", "Neoplasms", "Multiple Myeloma", "Neoplasms, Plasma Cell", "Myelodysplastic Syndromes", "Preleukemia", "Myeloproliferative Disorders", "Nervous System Neoplasms", "Central Nervous System Neoplasms", "Myelodysplastic-Myeloproliferative Diseases", "Plasmacytoma", "Lymphoproliferative Disorders"]}]